Aging Population And Healthcare Digitization Will Expand Radiotherapy Demand

Key Takeaways

• Rising global demand for radiotherapy and healthcare digitization position C-Rad for long-term growth, higher margins, and expanded market presence.
  
• Increased recurring service revenues and operational efficiencies are enhancing profit stability and buffering earnings against short-term fluctuations.
  
• Heavy reliance on large, region-specific orders and market timing exposes C-Rad to revenue volatility, cost pressures, and heightened risk from competition and regulatory challenges.

Catalysts

Develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.

• The global increase in cancer incidence and an aging population is leading to growing demand for radiotherapy, and there remains significant untapped market potential for C-Rad's positioning and monitoring solutions in both advanced and developing markets; as SGRT becomes standard of care and penetration rates rise, especially in developing regions, this is likely to boost long-term revenue growth.
  
• The accelerating digitization of healthcare and adoption of precision medicine are driving clinics to invest in technologies that ensure patient safety and workflow efficiency; C-Rad's advanced offerings and recent product innovations position it to benefit from this trend, supporting higher average selling prices (ASP) and gross margins.
  
• Expansion of recurring service contract revenue, which grew 86% YoY in Q2, is strengthening revenue visibility and reducing cyclicality, providing a buffer for earnings and supporting improved net margins over time as the installed base grows.
  
• C-Rad's continuous investments in R&D, integration with industry partners, and launches such as the new gating solution help it maintain technological leadership, which can drive new sales opportunities and sustain pricing power, positively impacting top-line revenue and gross margins.
  
• The company's ongoing operational efficiency measures, demonstrated by a 10% reduction in OpEx and a more streamlined cost structure, are supporting improvements in EBIT margin and should enhance future profitability even in the face of short-term revenue volatility.

C-Rad Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming C-Rad's revenue will grow by 10.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from 11.2% today to 18.5% in 3 years time.
• Analysts expect earnings to reach SEK 109.2 million (and earnings per share of SEK 2.84) by about July 2029, up from SEK 49.9 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 0.3x on those 2029 earnings, down from 25.4x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 28.4x.
• Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.6%, as per the Simply Wall St company report.

Risks

• C-Rad's revenue and EBIT have shown a notable decline year-on-year (revenue down 13% in constant currency, EBIT halved to SEK 8 million) mainly due to a softer order intake in 2024 and absence of prior China-related product deliveries, highlighting revenue volatility and potential earnings pressure if such one-off events or regional spikes are not repeated.
  
• Although service revenue and recurring contracts are growing, there is heavy dependence on large product orders and region-specific factors (e.g., post-registration boom in China or sudden market activity in EMEA), making the company's top-line results susceptible to concentration and timing risks, potentially affecting revenue predictability and margin stability.
  
• Market uncertainties such as U.S. trade tariffs have already generated customer hesitancy around capital expenditures versus operating expenses, and while C-Rad can currently pass on some tariff costs, sustained or escalated trade tensions could slow product demand or compress margins if price elasticity is reached, directly impacting revenue and profitability.
  
• While the company emphasizes operational cost control and improved efficiency, it faces scaling challenges as it seeks expansion in untapped and emerging markets with varied regulatory and reimbursement landscapes, which could drive up operating expenses and weigh on net margins if not managed precisely.
  
• Rising competition and requirements for technological differentiation (with mentions that sometimes competition comes down to price) mean that increasing R&D investment may be needed to maintain C-Rad's competitive position, risking margin erosion and potentially outpacing revenue growth if market adoption or pricing power weakens.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK45.0 for C-Rad based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK591.0 million, earnings will come to SEK109.2 million, and it would be trading on a PE ratio of 0.3x, assuming you use a discount rate of 5.6%.
• Given the current share price of SEK37.5, the analyst price target of SEK45.0 is 16.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.